BRPI0907613A2 - Composto de aril-2-feniletil-1-h-imidazol substituído como subtipo de moduladores seletivos de receptores adrenérgicos alfa 2b e/ou alfa 2c - Google Patents
Composto de aril-2-feniletil-1-h-imidazol substituído como subtipo de moduladores seletivos de receptores adrenérgicos alfa 2b e/ou alfa 2cInfo
- Publication number
- BRPI0907613A2 BRPI0907613A2 BRPI0907613-1A BRPI0907613A BRPI0907613A2 BR PI0907613 A2 BRPI0907613 A2 BR PI0907613A2 BR PI0907613 A BRPI0907613 A BR PI0907613A BR PI0907613 A2 BRPI0907613 A2 BR PI0907613A2
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- subtype
- phenylethyl
- substituted aryl
- adrenergic receptor
- Prior art date
Links
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/971,829 US7902247B2 (en) | 2008-01-09 | 2008-01-09 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| PCT/US2009/030074 WO2009089132A1 (en) | 2008-01-09 | 2009-01-05 | Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907613A2 true BRPI0907613A2 (pt) | 2015-07-21 |
Family
ID=40457040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907613-1A BRPI0907613A2 (pt) | 2008-01-09 | 2009-01-05 | Composto de aril-2-feniletil-1-h-imidazol substituído como subtipo de moduladores seletivos de receptores adrenérgicos alfa 2b e/ou alfa 2c |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7902247B2 (https=) |
| EP (1) | EP2240453A1 (https=) |
| JP (1) | JP2011509297A (https=) |
| AU (1) | AU2009204358A1 (https=) |
| BR (1) | BRPI0907613A2 (https=) |
| CA (1) | CA2711464A1 (https=) |
| WO (1) | WO2009089132A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002226225B2 (en) * | 2001-01-18 | 2008-03-20 | Dermavant Sciences GmbH | Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| BRPI0812385A2 (pt) * | 2007-05-23 | 2019-09-24 | Allergan Inc | lactamas cíclicas para o tratamento de glaucoma ou pressão intraocular elevada |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
| US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| HRP20141047T1 (hr) | 2008-08-01 | 2015-01-02 | Eye Therapies Llc | Pripravci za sužavanje krvnih žila i metode njihove uporabe |
| US12246013B2 (en) | 2008-08-01 | 2025-03-11 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
| JP2012517433A (ja) * | 2009-02-06 | 2012-08-02 | アラーガン インコーポレイテッド | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物 |
| US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
| US20110152271A1 (en) * | 2009-12-17 | 2011-06-23 | Gerald Horn | Compositions and methods for ophthalmic delivery of nasal decongestants |
| US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
| US9071616B2 (en) | 2010-11-18 | 2015-06-30 | Microsoft Technology Licensing, Llc | Securing partner-enabled web service |
| US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
| AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
| KR101537204B1 (ko) | 2012-05-08 | 2015-07-22 | 론자 아게 (론자 엘티디.) | 2-(2,3-디메틸페닐)-1-프로파날의 제조 방법 |
| US9045433B2 (en) * | 2012-05-08 | 2015-06-02 | Lonza Ltd. | Method for preparation of medetomidine |
| WO2012172119A2 (en) * | 2012-05-08 | 2012-12-20 | Lonza Ltd | Method for the preparation of medetomidine |
| CA2866441C (en) | 2012-06-28 | 2017-01-17 | Lonza Ltd. | Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal with chloroacetone |
| WO2013011157A1 (en) | 2012-06-28 | 2013-01-24 | Lonza Ltd | Method for preparation of medetomidine with chloroacetone |
| US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
| JP2019517524A (ja) * | 2016-06-02 | 2019-06-24 | パーデュー ファーマ エルピー | 疼痛治療のための微量アミン関連受容体１アゴニスト及び部分アゴニスト |
| WO2025171183A1 (en) * | 2024-02-06 | 2025-08-14 | Aglaeapharma Inc. | Imidazole containing compounds, derivatives therefore, and uses thereof |
| WO2025231265A1 (en) * | 2024-05-01 | 2025-11-06 | Alpherabio Llc | Combination with alpha-2 adrenergic receptor agonist |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU795462A3 (ru) | 1975-03-14 | 1981-01-07 | Эдьт Дьедьесерведьесети Дьяр (Фирма) | Способ получени тиокарбамидныхпРОизВОдНыХ |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| JPH032168A (ja) | 1989-03-30 | 1991-01-08 | Farmos Yhtymae Oy | アロマターゼ阻害活性を有する新規な４（５）―イミダゾール |
| US5212176A (en) | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
| GB9125924D0 (en) * | 1991-06-18 | 1992-02-05 | Orion Yhtymae Oy | Stereoisomers of an imidazole derivative |
| GB9310965D0 (en) * | 1993-05-27 | 1993-07-14 | Ucb Sa | 2-hydroxy-3-(1h-imidazol-4-yl)alkyl)benzenecarboximidamides |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| PL341009A1 (en) | 1997-12-04 | 2001-03-12 | Allergan Sales | Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors |
| TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| WO2006036507A1 (en) * | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| RU2008130448A (ru) | 2006-01-27 | 2010-03-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Применение производных 4-имидазола для расстройств цнс |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| AU2009205539B2 (en) * | 2008-01-18 | 2013-12-05 | Allergan.Inc | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| US8063231B2 (en) * | 2008-06-09 | 2011-11-22 | Allergan, Inc. | Methods of treating alpha adrenergic mediated conditions |
| ES2672777T3 (es) * | 2008-06-09 | 2018-06-18 | Allergan, Inc. | Métodos de tratamiento de estados con mediación alfa-adrenérgica |
-
2008
- 2008-01-09 US US11/971,829 patent/US7902247B2/en active Active
-
2009
- 2009-01-05 EP EP09700891A patent/EP2240453A1/en not_active Withdrawn
- 2009-01-05 AU AU2009204358A patent/AU2009204358A1/en not_active Abandoned
- 2009-01-05 CA CA2711464A patent/CA2711464A1/en not_active Abandoned
- 2009-01-05 JP JP2010542297A patent/JP2011509297A/ja active Pending
- 2009-01-05 BR BRPI0907613-1A patent/BRPI0907613A2/pt not_active IP Right Cessation
- 2009-01-05 WO PCT/US2009/030074 patent/WO2009089132A1/en not_active Ceased
-
2010
- 2010-12-13 US US12/966,560 patent/US8735438B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011509297A (ja) | 2011-03-24 |
| US7902247B2 (en) | 2011-03-08 |
| US20110077274A1 (en) | 2011-03-31 |
| EP2240453A1 (en) | 2010-10-20 |
| WO2009089132A1 (en) | 2009-07-16 |
| AU2009204358A1 (en) | 2009-07-16 |
| US8735438B2 (en) | 2014-05-27 |
| CA2711464A1 (en) | 2009-07-16 |
| US20090176843A1 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907613A2 (pt) | Composto de aril-2-feniletil-1-h-imidazol substituído como subtipo de moduladores seletivos de receptores adrenérgicos alfa 2b e/ou alfa 2c | |
| LTC2291080I2 (lt) | Sfingozino fosfato receptorių nauji moduliatoriai | |
| BRPI0917634A2 (pt) | benzoxazolas, benztiazolas e análogos relacionados como moduladores de sirtuína | |
| BRPI0914006A2 (pt) | benzimidazóis e análogos relacionados como moduladores de sirtuína | |
| BRPI0907844A2 (pt) | moduladores seletivos do receptor de andrógeno | |
| EP2362779A4 (en) | CXCR4 RECEPTOR COMPOUNDS | |
| BRPI0907180A2 (pt) | Randomização de alocação de recursos | |
| BRPI0909375A2 (pt) | Moduladores de receptores de quimiocinas | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| EP2326631A4 (en) | MIF MODULATORS | |
| BRPI0923885A2 (pt) | Criação de identificador único global de um dispositivo de assinante | |
| BRPI0906773A2 (pt) | Alocação de recursos compartilhados | |
| BRPI0908918A2 (pt) | corpo revestido de material de elevada resistência | |
| BRPI0908924A2 (pt) | Corpo revestido de material de elevada resistência | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| BRPI1014096A2 (pt) | manta fibrosa estruturada | |
| BRPI0717023A2 (pt) | Tiazol pirazolopirimidina como antagonistas do receptor de crf1 | |
| CR10926A (es) | Nuevas 2-aminooxazolinas como ligandos taar1 | |
| BRPI0922597A8 (pt) | ftalazinona e análogos relacionados como moduladores de sirtuína | |
| BRPI0910585A2 (pt) | indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7 | |
| BRPI0915747A2 (pt) | conversor de fluxo | |
| DK2297100T3 (da) | Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer | |
| EP2379510A4 (en) | quinazolinone | |
| BRPI0906927A2 (pt) | Compostos de substituída-aril-(imidazol)-metil)-fenila como moduladores seletivos de subtipo de receptores alfa 2b e/ou alfa 2c adrenérgicos | |
| EP2242580A4 (en) | ZIEGLER-NATTA CATALYST |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |